Australian expressed RNAi firm Benitec Biopharma provided an update on its research and development activities late last month, reporting that it remains on track to move its lead drug candidate, the hepatitis C therapy TT-034, into the clinic as early as this month.

Meanwhile, the company's chemotherapy-resistant lung cancer treatment Tribetarna is on track to enter human trials in late 2014.